U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
| Bayer Aktiengesellschaft American Depositary Shares (AMEX: BAYRY) | Delayed: 12.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.07 | 52 Week High | $135.54 | |||
| Open | $12.07 | 52 Week Low | $94.36 | |||
| Day High | $12.07 | P/E | N/A | |||
| Day Low | $12.07 | EPS | $0.00 | |||
| Volume | 12 | |||||
| Bayer AG (AMEX: BAYZF) | Delayed: 48.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.00 | 52 Week High | $135.00 | |||
| Open | $48.00 | 52 Week Low | $94.95 | |||
| Day High | $48.00 | P/E | N/A | |||
| Day Low | $48.00 | EPS | $0.00 | |||
| Volume | 29 | |||||
